Key result
Ropivacaine maintains ~13% higher normalized cardiac output at 5 minutes vs bupivacaine during cesarean delivery.
Why the study?
Most studies evaluating ropivacaine versus bupivacaine during combined spinal and epidural anesthesia have focused only on blood pressure and heart rate, leaving detailed hemodynamic parameters such as cardiac output, preload, and afterload incompletely characterized.
Does ropivacaine improve cardiac output at 5 minutes compared to bupivacaine in women undergoing elective cesarean delivery under combined spinal-epidural anesthesia?
RCT (n=82)
Double-blind
Block randomization
No
Does ropivacaine improve cardiac output at 5 minutes compared to bupivacaine in women undergoing elective cesarean delivery under combined spinal-epidural anesthesia?
Absolute Event Rate: 92.7% vs 79.8%
p-value: p=0.001
Ropivacaine better preserves maternal cardiac output and reduces the incidence of hypotension compared to bupivacaine during elective cesarean delivery under combined spinal-epidural anesthesia.
Supports preferring ropivacaine over bupivacaine to preserve cardiac output in cesarean delivery; confirms hemodynamic advantages in this RCT.
Women with term pregnancies undergoing cesarean delivery under combined spinal and epidural anesthesia (CSEA) usually present with hemodynamic variability and a high incidence of hypotension. Among the commonly used anesthetic drugs for CSEA, ropivacaine reduces the incidence of hypotension compared with bupivacaine. However, most studies have focused on blood pressure and heart rate measurements to evaluate the effects of these two anesthetic drugs on parturients. This study aimed to compare maternal cardiac output and hemodynamic parameters, such as cardiac preload and afterload, of ropivacaine and bupivacaine using transthoracic echocardiography. Eighty-two parturients scheduled for elective caesarean deliveries under CSEA anesthesia were randomly assigned to receive 0.5% bupivacaine 7.5–8.5 mg (n = 41) or 0.5% ropivacaine 11-12.5 mg (n = 41) with different medication doses used for different height-ranges. Cardiac output, stroke volume (SV), ejection fraction, end-diastolic volume, end-diastolic volume, and systemic vascular resistance (SVR) were measured using transthoracic echocardiography before anesthesia; at 1, 5, and 10 min after CSEA; at delivery; and 1–2 min after the oxytocin administration. The primary outcome was the change in cardiac output (CO) at 5 min. Secondary outcomes included maternal hemodynamic, anesthetic efficacy, maternal side effects and fetal outcome data. Normalized cardiac output was higher in the ropivacaine group at 5 min after CSEA (92.7%; 95% confidence interval (CI): 87.1–98.3%) than in the bupivacaine group (79.8%; 95% CI: 74.2–85.3%) (P = 0.001). CO, SV, end-diastolic volume, and blood pressure were greater, systemic vascular resistance and phenylephrine dosage were lower, and the incidence of bradycardia was lower in the ropivacaine group. The 1-minute Apgar score was higher in the ropivacaine group (P = 0.043). Other neonatal outcomes were similar between the groups. Compared to bupivacaine, ropivacaine demonstrated higher cardiac output (CO), stroke volume (SV), blood pressure, and an improved 1-minute neonatal Apgar score in elective cesarean deliveries under combined spinal-epidural anesthesia (CSEA). Registration number: ChiCTR220006454. Date of registration: October 11, 2022.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) conducted an RCT in Elective cesarean delivery (n=82). Ropivacaine vs. 0.5% bupivacaine 7.5-8.5 mg was evaluated on Normalized cardiac output at 5 minutes post-anesthesia (p=0.001). Ropivacaine maintained a significantly higher normalized cardiac output at 5 minutes compared to bupivacaine (92.7% vs 79.8%) during elective cesarean delivery under combined spinal-epidural anesthesia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: